Upadhyay Suketu 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) Director Suketu Upadhyay Receives Award
What Happened
Suketu Upadhyay, a director of Vertex Pharmaceuticals (VRTX), was granted 80.508 deferred stock units (DSUs) on 2026-04-15. The grant is recorded at $442.50 per share for a total value of $35,625. This was an award/compensation (transaction code A) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-04-15; filing date: 2026-04-17 (appears timely).
- Instrument: 80.508 deferred stock units (derivative award) at $442.50 per unit; total value $35,625.
- Shares owned after transaction: not reported in this Form 4.
- Footnote: Each DSU represents one share of common stock and will be paid out in common stock upon the earliest of (i) Mr. Upadhyay’s board service termination, (ii) a change of control, or (iii) his disability or death.
- Transaction type: Award/Grant (A); derivative, restricted until payout conditions are met.
Context
This is a typical director compensation grant (deferred stock units) and not an immediate purchase or sale. Because the DSUs convert to actual shares only upon specified events, they are restricted and do not indicate an immediate change in market exposure.
Insider Transaction Report
Form 4
Upadhyay Suketu
Director
Transactions
- Award
Deferred Stock Units
[F1]2026-04-15$442.50/sh+80.508$35,625→ 2,799.156 total→ Common Stock (80.508 underlying)
Footnotes (1)
- [F1]Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-04-17